<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="21512">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01660412</url>
  </required_header>
  <id_info>
    <org_study_id>31337</org_study_id>
    <nct_id>NCT01660412</nct_id>
  </id_info>
  <brief_title>Does Alkalinization Reduce Perceived Pain Levels During Sentinel Lymph Node Imaging?</brief_title>
  <acronym>buffering SLN</acronym>
  <official_title>Does Alkalinization of Technetium-99m Sulfur Colloid Reduce Perceived Pain Levels During Non-breast Sentinel Lymphoscintigraphy?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Arkansas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Howard J Barnhard, Resident Research Endowment.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>UAMS DEPT of Radiology.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Arkansas</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pain during nuclear medicine breast lymphnode detection procedures has been reported as high
      as 8.8/10.  Using Sodium Bicarbonate to alkalinize the radio-pharmaceutical injection, pain
      can safely be reduced from 6.6/10 to 4.7/10, during breast lymph node detection procedures.

      In sites other then the breast, using Bicarbonate to make the injection's pH closer to
      natural, attempts to lower the pain levels will be performed.

      Hypothesis: The perceived pain level during non breast sentinel lymph node techniques can be
      reduced by raising the pH of the injectate (Tc-99m SC) to near the physiologic level of pH
      7.40.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2012</start_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Perceived Pain level</measure>
    <time_frame>immediately after administration (&lt;1 min)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Immediately after receiving an injection, subjects will rate their perceived pain level, using a validated measure.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>pH altered first</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The first injection administered will be the pH altered solution.  The second injection will be the standard of care solution (opposite order).  The remaining injections will be randomly assigned as either standard of care or pH altered.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care first</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The first injection administered will be the standard of care solution (SOC).  The second injection will be the pH altered solution.  The remaining injections will be randomly assigned as either standard of care or pH altered.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard of Care First</intervention_name>
    <description>For the second injection, and randomly after that, Sodium Bicarbonate will be compounded with Tc-99m SC, to raise the pH up to ~7.40.</description>
    <arm_group_label>Standard of Care first</arm_group_label>
    <other_name>Sodium Bicarbonate second</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ph Altered first</intervention_name>
    <description>For the first injection, Sodium Bicarbonate will be compounded with Tc-99m SC, to raise the pH up to ~7.40.  For the second injection, the standard of care will be given, and randomly after that either standard of care, or pH altered will be given.</description>
    <arm_group_label>pH altered first</arm_group_label>
    <other_name>Sodium Bicarbonate first</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients presenting for SLN imaging for melanoma or who have had an excisional biopsy
             for melanoma of the thorax and appendicular structures;

          -  Patients scheduled to receive two or more injections of Tc-99m SC for the purpose of
             clinical management of melanoma or who have had an excisional biopsy for melanoma of
             the thorax and appendicular structures.

        Exclusion Criteria:

          -  Patients presenting for SLN imaging of lesions involving the breast, ear, nose, and
             genitourinary regions;

          -  Patients scheduled to receive only a single injection of Tc-99m SC;

          -  Pregnant or breast feeding women.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James A Ntambi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UAMS</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>James A Ntambi, MD</last_name>
    <phone>5016866901</phone>
    <email>jantambi@uams.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nicki Hilliard, Pharm D</last_name>
    <phone>501 686 6398</phone>
    <email>nlhilliard@uams.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UAMS</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ntambi A James, MD</last_name>
      <phone>501-686-6901</phone>
      <email>jantambi@uams.edu</email>
    </contact>
    <investigator>
      <last_name>Ntambi A James, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Fetzer S, Holmes S. Relieving the pain of sentinel lymph node biopsy tracer injection. Clin J Oncol Nurs. 2008 Aug;12(4):668-70.</citation>
    <PMID>18676334</PMID>
  </reference>
  <reference>
    <citation>Stojadinovic A, Peoples GE, Jurgens JS, Howard RS, Schuyler B, Kwon KH, Henry LR, Shriver CD, Buckenmaier CC. Standard versus pH-adjusted and lidocaine supplemented radiocolloid for patients undergoing sentinel-lymph-node mapping and biopsy for early breast cancer (PASSION-P trial): a double-blind, randomised controlled trial. Lancet Oncol. 2009 Sep;10(9):849-54. Epub 2009 Aug 5.</citation>
    <PMID>19664956</PMID>
  </reference>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 27, 2014</lastchanged_date>
  <firstreceived_date>August 3, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pain</keyword>
  <keyword>Alkalinization</keyword>
  <keyword>Technetium 99m Sulfur Colloid</keyword>
  <keyword>sentinel lymphoscintigraphy?</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
